| Literature DB >> 34328501 |
Kristina Aspvall1,2, Filipa Sampaio3, Fabian Lenhard1, Karin Melin4,5, Lisa Norlin5, Eva Serlachius1,2, David Mataix-Cols1,2, Erik Andersson6.
Abstract
Importance: Therapist-guided, internet-delivered cognitive behavioral therapy is an effective treatment option for children and adolescents with obsessive-compulsive disorder, but to our knowledge, its cost-effectiveness compared with traditional in-person treatment has not been established. Objective: To evaluate the cost-effectiveness of guided internet-delivered cognitive behavioral therapy implemented within a stepped-care model compared with in-person cognitive behavioral therapy for young people with obsessive-compulsive disorder. Design, Setting, and Participants: This economic evaluation of a randomized noninferiority trial conducted at 2 specialist obsessive-compulsive disorder clinics in Sweden enrolled 152 children and adolescents aged 8 to 17 years with obsessive-compulsive disorder, mainly through clinician referrals (110 [72%]). Recruitment began October 6, 2017, and ended May 24, 2019. Follow-up ended April 14, 2020. Interventions: Participants were randomly assigned to receive either guided internet-delivered cognitive behavioral therapy or in-person cognitive behavioral therapy during a 16-week period. At the 3-month follow-up, nonresponders in both groups were offered additional in-person cognitive behavior therapy sessions. Main Outcomes and Measures: Health outcomes were treatment response rates (primary outcome), remission rates, and quality-adjusted life-years. Cost data were collected before treatment, after treatment, at 3-month follow-up, and at 6-month follow-up (primary end point) and are presented in 2020 US dollars. The differences in incremental costs and health outcomes were compared between the groups and presented from the health care professional, health care sector, and societal perspectives.Entities:
Mesh:
Year: 2021 PMID: 34328501 PMCID: PMC8325072 DOI: 10.1001/jamanetworkopen.2021.18516
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Sociodemographic and Clinical Characteristics of the Sample
| Characteristic | Participants, No. (%) | |
|---|---|---|
| Stepped-care (n = 74) | In-person CBT (n = 78) | |
| Sex | ||
| Girls | 46 (62) | 48 (62) |
| Boys | 28 (38) | 30 (39) |
| Age, mean (SD) [range], y | 13.4 (2.6) [8-17] | 13.4 (2.5) [8-17] |
| Educational level of parent | ||
| Primary school | 2 (3) | 0 |
| Secondary school | 8 (11) | 8 (10) |
| College or university | ||
| <2 y | 8 (11) | 8 (10) |
| ≥2 y | 53 (72) | 60 (77) |
| Doctorate | 3 (4) | 2 (3) |
| Occupational status of parent | ||
| Working | 68 (92) | 75 (96) |
| Student | 0 | 3 (4) |
| On sick leave | 6 (8) | 0 |
| Comorbidity | ||
| None | 50 (68) | 50 (64) |
| Depressive episode | 6 (8) | 12 (15) |
| Anxiety disorders | ||
| Specific phobia | 9 (12) | 6 (8) |
| Social phobia | 4 (5) | 4 (5) |
| GAD | 4 (5) | 3 (4) |
| Panic disorder | 1 (1) | 2 (3) |
| Separation anxiety | 1 (1) | 2 (3) |
| Health anxiety | 0 | 1 (1) |
| Tic disorder | 6 (8) | 8 (10) |
| ADHD | 6 (8) | 4 (5) |
| Eating disorder | 1 (1) | 0 |
| Medication (ongoing) | ||
| None | 69 (93) | 74 (95) |
| SSRI | 2 (3) | 3 (4) |
| Sleep hormone | 2 (3) | 2 (2) |
| Central stimulants | 2 (3) | 0 |
| Antihistamine | 0 | 0 |
| Baseline CY-BOCS score, mean (SD) [range] | 22.96 (3.64) [16-32] | 22.95 (3.70) [17-33] |
| Baseline total societal costs, mean (SD), $ | 3479 (3907) | 3098 (3396) |
| Source of referral | ||
| Clinician | 54 (73) | 56 (72) |
| Self | 20 (27) | 22 (28) |
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CBT, cognitive behavioral therapy; CY-BOCS, Children’s Yale-Brown Obsessive-Compulsive Scale; GAD, generalized anxiety disorder; SSRI, selective serotonin-reuptake inhibitors.
The parent mainly responsible for study participation.
CY-BOCS scores range from 0 to 40, with higher scores indicating more severe symptoms.
Unit Costs and Sources
| Resource item | Unit cost, $ | Source |
|---|---|---|
| Healthcare resources (per visit) | ||
| General practitioner | 202.91 | Region Stockholm |
| Nurse, counselor, or physiotherapist | 90.18 | Region Stockholm |
| Specialist practitioner | 450.22 | Sweden’s municipalities and regions |
| Psychologist | 381.24 | Sweden’s municipalities and regions |
| Speech and language therapist | 285.88 | Region Stockholm |
| Dietician | 328.71 | Region Stockholm |
| Medication | ||
| Medicines | Individual product prices | The Dental and Pharmaceutical Benefits Agency of Sweden |
| Dietary supplements | Individual product prices | Market price from Swedish pharmacy |
| Support and assistance | ||
| Specialist teacher | 22.81 | Own estimate |
| Study help | 50.48 | Own estimate |
| Support from family and friends | 17.06 | Estimated as cost of leisure time |
| Personal assistant | 34.30 | Swedish Insurance Agency |
| Support family | 76.88 | Sweden’s municipalities and regions |
| Productivity losses | ||
| Cost per child/d at school | 82.74 | Own estimate based on Swedish National Agency for Education |
| Average wage/h in Sweden | 34.93 | Statistics Sweden |
| Cost of leisure time/h | 17.06 | Posttax wage/h in Sweden[ |
| Intervention cost | ||
| Psychologist/h | 381.24 | Sweden’s municipalities and regions |
All costs uprated to 2020 US dollars.
Based on a mean of 9 medical specialties.
Includes social fees of 43.3%.
Cost and Outcomes Over the Trial Period
| Cost category | Observed mean (SE) | Mean difference | ||
|---|---|---|---|---|
| Stepped-care (n = 74) | In-person CBT (n = 78) | Unadjusted | Adjusted (95% CI) | |
| Before multiple imputation | ||||
| Health care visits | 2580 (673) | 2093 (300) | 485 | 59 (−176 to 666) |
| Support and assistance | 406 (121) | 607 (183) | −207 | 5 (−74 to 733) |
| Medication/supplements | 83 (38) | 63 (15) | 19 | −9 (−14 to 21) |
| Parental unpaid productivity loss | 1500 (616) | 1541 (441) | −41 | 38 (−95 to 586) |
| Parental paid productivity loss | 926 (166) | 1806 (429) | −937 | 7 (−135 to 1184) |
| Child school absenteeism | 1091 (221) | 1361 (233) | −274 | −75 (−149 to 135) |
| Child school presenteeism | 905 (309) | 826 (173) | 79 | 47 (−97 to 697) |
| Total intervention costs | 3343 (200) | 5395 (364) | −2104 | −2104 (−3006 to −1202) |
| Step 1 | 2140 (112) | 4713 (136) | ||
| Step 2 | 3066 (107) | 3323 (112) | ||
| Total health care costs | 6137 (492) | 7684 (404) | −1569 | −1688 (−2133 to −919) |
| Total societal costs | 10 917 (1188) | 13 825 (1212) | −2955 | −1723 (−2381 to −601) |
| After multiple imputation | ||||
| Total health care costs | 6081 (605) | 7527 (492) | −1445 | −1530 (−2076 to −588) |
| Total societal costs | 10 755 (1360) | 13 592 (1199) | −2837 | −1748 (−2488 to −483) |
| Responders | 0.676 | 0.675 | 0.0004 | 0.0004 (−0.151 to 0.152) |
| Remitters | 0.486 | 0.597 | −0.111 | −0.111 (−0.271 to 0.049) |
| Total QALYs (child) | 0.620 (0.009) | 0.636 (0.008) | −0.017 | −0.029 (−0.055 to 0.006) |
Abbreviations: CBT, cognitive behavioral therapy; QALYs, quality-adjusted life-years.
Costs are for the whole trial period of 10 months and are presented in 2020 US dollars.
Responders, remitters, and total intervention costs were not adjusted. Adjusted mean differences for other costs were calculated using generalized linear models adjusted for baseline societal cost. Total QALYs were adjusted for baseline Child Health Utility 9 Dimensions utilities.
Housework.
Work absenteeism.
Including intervention costs.
Figure. Cost-effectiveness Planes Using Responder Status as Primary Health Outcome
Cost-effectiveness planes with responder status as health outcome from the health care professional perspective (A), the health care sector perspective (B), and the societal perspective (C). Each plane has 4 quadrants. Dots in the northwest (NW) quadrant indicate that stepped care is more costly and less effective. Dots in the northeast (NE) quadrant indicate that stepped care is both more costly and more effective. Dots in the southwest (SW) quadrant indicate that stepped care is both less costly and less effective. Dots in the southeast (SE) quadrant indicate that stepped care is less costly and more effective.